Genetic fingerprints help predict sarcoma outcome:
This article was originally published in Clinica
Executive Summary
US researchers have developed a genetic fingerprint of each type of adult soft tissue sarcoma, which they say will improve their diagnosis and enhance the prediction of patient outcome. The genetic fingerprints, which were identified using oligonucleotide array analysis, will be useful in cases where pathologists disagree about a diagnosis or when the appearance of tumour cells does not conclusively link them to a particular subtype, say researchers led by Dr Robert Maki, of the Memorial Sloan-Kettering Cancer Center in New York.
You may also be interested in...
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.